Observation on the effect of modified Yiqi Buxue Yangyin Decoction combined with DP/C chemotherapy in advanced non-small cell lung cancer
Objective To explore the practical effect of modified Yiqi Buxue Yangyin Decoction combined with DP/C chemotherapy in advanced non-small cell lung cancer(NSCLC).Methods 94 patients with advanced non-small cell lung cancer were divided into a control group and an observation group according to different treatment methods,with 47 cases in each group.The control group was treated with DP/C chemotherapy,and the observation group was treated with modified Yiqi Buxue Yangyin Decoction and DP/C chemotherapy.The treatment effect,tumor-related markers[carbohydrate antigen 19-9(CA19-9),cytokeratin 19 fragment antigen 21-1(CYFRA21-1),carcinoembryonic antigen(CEA)]level,traditional Chinese medicine syndrome score,and the incidence of adverse reactions of the two groups were compared.Results The disease control rate(DCR)in the observation group was 74.47%,which was higher than 53.19%in the control group(χ2=4.608,P=0.032<0.05).The levels of CA19-9,CYFRA21-1 and CEA in the observation group were(32.17±5.54)U/ml,(2.77±0.81)ng/ml and(8.05±0.88)μg/L,which were lower than(35.54±5.21)U/ml,(3.34±0.89)ng/ml and(9.12±0.97)μg/L in the control group(P<0.05).The scores of cough,bloody phlegm,fatigue and night sweat in the observation group were(1.23±0.25),(1.68±0.32),(1.32±0.37)and(1.51±0.35)points,which were lower than(2.12±0.36),(2.34±0.54),(1.98±0.49)and(1.89±0.42)points in the control group(P<0.05).The observation group had incidence of adverse reactions of 6.38%,which was lower than 21.28%in the control group(χ2=4.374,P=0.036<0.05).Conclusion For patients with advanced non-small cell lung cancer,modified Yiqi Buxue Yangyin Decoction combined with DP/C chemotherapy can improve the expression of tumor-related markers,improve patients'traditional Chinese medicine syndrome score,reduce adverse reactions,and then improve the treatment effect.
万方数据
维普
